By Mrinalika Roy and Kamal Choudhury

(Reuters) – The U.S. Food and Drug Administration issued warning letters to Eli Lilly, Novo Nordisk and telehealth firm Hims & Hers Health last week as part of President Donald Trump’s order to crack down on drug advertising.

The FDA website shows dozens of letters issued on September 9, many to companies that make or sell weight-loss drugs, the day Trump signed an executive order on disclosure in direct-to-consumer prescription drug advertising. The order instructed the FDA to step up enforcement of laws against misleading ads.

The FDA’s letters to Lilly cite three media interviews, including a 2024 Oprah Winfrey special, where company representatives discussed Zepbound and Mounjaro but, according to regulators, omitted or downplayed boxed warnings

See Full Page